Information Provided By:
Fly News Breaks for November 6, 2019
XLRN
Nov 6, 2019 | 15:42 EDT
Piper Jaffray analyst Danielle Brill said "suboptimal responses" in myelofibrosis patients not on background ruxolitib "caused a lot of initial confusion" this morning, but after the company's earnings call she believes the data "look better than our initial read." The analyst, who thinks management "is clearly bullish, the data appear fine, and importantly the addressable market doesn't appear to be impacted to the extent we first thought," keeps an Overweight rating on Acceleron shares and bumped up her price target on the stock to $73 from $71.
News For XLRN From the Last 2 Days
There are no results for your query XLRN